A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants with Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Latest Information Update: 17 Feb 2025
At a glance
- Drugs CYB 003 (Primary)
- Indications Anxiety; Depression; Major depressive disorder
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2025 New trial record